JavaScript is disabled in your browser. Please enable JavaScript to view this website.

Navigate the complexity of gene fusions in heme malignancy research

Gene fusions in hematologic malignancies can be structurally complex, heterogeneous, and associated with genes that have many possible partners. Methods that require prior knowledge of both fusion partners may limit discovery of rare or novel events and can require multiple targeted approaches to cover a broad fusion landscape.
IDT logo

One workflow for clear heme insights

FUSIONPlex Heme Solutions use AMP chemistry and anchored gene-specific primers to identify known and novel fusion partners. By targeting RNA to capture expressed fusion transcripts, the solution avoids the economic and technical challenges that come from sequencing large, repeat-rich intronic regions in DNA-based assays.

Reliable fusion identification for hematologic malignancy questions that matter most

Archer FUSIONPlex Heme Solutions are designed to detect 1,220+ known, rare, and novel gene fusions across hematologic malignancy research applications. A single-sided, anchored priming strategy requires prior knowledge of only one fusion partner, enabling identification of fusion events that may be challenging to characterize using approaches that require both fusion partners to be known in advance.

Performance testing demonstrated identification of over 85% of expected fusions in samples containing 10% fusion-positive material, supporting reliable fusion discovery even in low tumor content research samples. Strong fusion signal recovery was observed across multiple fusion types and representative cell-line models, highlighting the solution's ability to identify diverse rearrangement events.

The workflow is paired with Archer Analysis for de novo read assembly, visualization, and interpretation, while supporting customization as new biomarkers emerge.

Designed for fusion discovery, flexibility, and practical end-to-end use

  • Identifies known and novel fusion partners using AMP chemistry
  • Supports broad heme malignancy research with catalog and customizable panel options
  • Uses a consistent library preparation workflow with integrated Archer Analysis
  • Scales from focused studies to higher-throughput research projects

For WSAW Archer Heme

Speak to one of our leading life sciences experts

TTAE

TTAE

546006278

TTAE

add

Talk to an Expert

https://lifesciences.danaher.com/

https://lifesciences.danaher.com/us/en/solutions/gene-therapy/crispr-gene-mediated.html